-
-
Credits Available
Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™
You Are Eligible For
Target Audience and Goal Statement
This activity was developed for clinicians who manage patients with cardiovascular disease.
The goals of this program are for clinicians to:
- Personalize the intensity and duration of dual antiplatelet therapy (DAPT) to optimize clinical outcomes after percutaneous
coronary intervention (PCI)
- Incorporate more potent and extended DAPT into the treatment of patients with type 2 diabetes
- Utilize antiplatelet therapy strategies to reduce bleeding risk in patients with high bleeding risk (HBR) after PCI
- Explain considerations that help determine the choice between DAPT and dual pathway inhibition (DPI), and use extended dual
therapy in appropriate patients to reduce ischemic risk
Learning Objectives
Upon completion of this activity, participants will:
- Discuss the multiple factors to be considered when assessing ischemic risk and bleeding risk after PCI
- Recognize diabetes mellitus as a criterion for increased ischemic risk
- Identify patients at HBR and interpret clinical evidence using bleeding risk-reduction strategies with antiplatelet therapy
- Describe factors for consideration of extended DAPT or DPI and explain clinical trial results
Disclosures
Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored
educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding
24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services
consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity
or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate,
and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that
are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent
of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which
they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships
have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether
the speaker's interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the
audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.
Chair
Faculty

-
Marc P. Bonaca, MD, MPH
Executive Director, CPC Clinical Research
Director of Vascular Research
Associate Professor of Medicine
William R. Hiatt Endowed Chair in Cardiovascular Research
University of Colorado School of Medicine
Aurora, Colorado
Disclosures
Marc P. Bonaca, MD, MPH, has the following relevant financial relationships:
Dr. Bonaca is the Executive Director of CPC, a non-profit academic research organization affiliated with the University of
Colorado, that receives:
Research grant/consulting funding: Abbott; Agios; Alexion Pharma; Alnylam; Amgen; Angionetics; ARCA Biopharma; Array; AstraZeneca; Atentiv; Audentes; Bayer; Better Therapeutics; Brigham and Women’s Hospital; Bristol Myers Squibb; Cardiol Therapeutics; CellResearch; Cook; Cook Medical; CSL Behring; Eidos Therapeutics; EP Trading Co; Esperion Therapeutics; EverlyWell; Faraday; Fortress Biotech; HDL Therapeutics; Heartflow; Hummingbird Bioscience; Insmed; Janssen; Kowa Research; Lexicon; Merck; Medtronic; Moderna; Novate Medical; Novo Nordisk; Pfizer, Inc.; PhaseBio; PPD Development; Prairie Education and Research; Prothena Biosciences; Regeneron; Regio Biosciences; Sanifit Therapeutics; Sanofi; Smith and Nephew; Stealth BioTherapeutics; University of Colorado; Worldwide Clinical Trials; WraSer; Yale Cardiovascular Research Group
Stock (Dr. Bonaca): Medtronic; Pfizer, Inc
Consultant: Audentes

-
Roxana Mehran, MD
Mount Sinai Endowed Professor of Cardiovascular Clinical Research and Outcomes
Professor of Medicine, and Population Health Science and Policy
Director of Interventional Cardiovascular Research and Clinical Trials
Director of Women’s Cardiovascular Health at Mount Sinai
Icahn School of Medicine at Mount Sinai
New York, New York
Disclosures
Roxana Mehran, MD, has the following relevant financial relationships:
Research Funding to Institution: Abbott; Abiomed; Alleviant Medical; AM-Pharma; Amgen; Arena; AstraZeneca; Atricure; Bayer;
Biosensors; Biotronik; Boston Scientific; Bristol Myers Squibb; CardiaWave; CeloNova; Chiesi; Concept Medical; CSL Behring;
Cytosorbents; Daiichi Sankyo; Element Science; Faraday; Humacyte; Idorsia Pharmaceuticals; Janssen; Medtronic; Novartis; OrbusNeich;
PhaseBio; Philips; Pi-Cardia; RenalPro; Shockwave; Vivasure; Zoll
Personal Fees: Cine-Med Research; WebMD
Stock: Applied Therapeutics; ControlRad (spouse); Elixir Medical; STEL
Scientific Advisory Board: AMA; ACC; (BOT Member); SCAI (Women in Innovations Committee Member), JAMA Associate Editor; Faculty
CRF (no fee)
Voxmedia
Accreditation Statements
Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical
education for physicians.
For questions regarding the content of this activity, contact the
accredited provider for this CME/CE activity noted above. For technical
assistance, contact [email protected]
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 80% on the post-test.
Follow these steps to earn CME/CE credit*:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or printed out.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated
at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.